These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 4718678)

  • 21. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.
    Chello PL; Sirotnak FM; Dorick DM; Donsbach RC
    Cancer Res; 1977 Dec; 37(12):4297-303. PubMed ID: 922722
    [No Abstract]   [Full Text] [Related]  

  • 22. Studies of inhibition of tumour cell DNA synthesis by immune cells in Gross virus induced leukemia.
    Finklestein JZ; Byfield J; Tittle K; Imagawa DT
    Rev Eur Etud Clin Biol; 1972 Mar; 17(3):287-92. PubMed ID: 5053619
    [No Abstract]   [Full Text] [Related]  

  • 23. On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia.
    Sirotnak FM; Kurita S; Hutchison DJ
    Cancer Res; 1968 Jan; 28(1):75-80. PubMed ID: 5635374
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of triamterene on nucleic acid synthesis.
    Chang JC; Hall TC
    Clin Pharmacol Ther; 1972; 13(3):372-6. PubMed ID: 5026377
    [No Abstract]   [Full Text] [Related]  

  • 25. Interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis.
    Bruckner HW; Schreiber C; Waxman S
    Cancer Res; 1975 Mar; 35(3):801-6. PubMed ID: 1116135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells.
    Cohen M; Bender RA; Donehower R; Myers CE; Chabner BA
    Cancer Res; 1978 Sep; 38(9):2866-70. PubMed ID: 679194
    [No Abstract]   [Full Text] [Related]  

  • 27. The metabolic fate of tritiated methotrexate. I. Absorption, excretion, and distribution in mice, rats, dogs and monkeys.
    Henderson ES; Adamson RH; Denham C; Oliverio VT
    Cancer Res; 1965 Aug; 25(7):1008-17. PubMed ID: 4954195
    [No Abstract]   [Full Text] [Related]  

  • 28. Sites of action of amethopterin: intrinsic and acquired drug resistance.
    Harrap KR; Hill BT; Furness ME; Hart LI
    Ann N Y Acad Sci; 1971 Nov; 186():312-24. PubMed ID: 5289423
    [No Abstract]   [Full Text] [Related]  

  • 29. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 30. Improved methotrexate therapy of murine tumors obtained by probenecid-mediated pharmacological modulation at the level of membrane transport.
    Sirotnak FM; Moccio DM; Hancock CH; Young CW
    Cancer Res; 1981 Oct; 41(10):3944-9. PubMed ID: 7285003
    [No Abstract]   [Full Text] [Related]  

  • 31. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
    Chabner BA; Young RC
    J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycocalyx of tumor cells.
    Roth J; Stiller D; Block F
    Exp Pathol (Jena); 1972; 6(1):35-46. PubMed ID: 4259824
    [No Abstract]   [Full Text] [Related]  

  • 33. Prediction of methotrexate responsiveness of tumors in man.
    Bertino JR; Hryniuk WM; Capizzi R
    Natl Cancer Inst Monogr; 1971 Dec; 34():179. PubMed ID: 5291100
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of day of dosage omission on survival time in the regularly scheduled methotrexate (NSC-740) treatment of leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):25-30. PubMed ID: 5030806
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1972 Oct; 32(10):2120-6. PubMed ID: 4404161
    [No Abstract]   [Full Text] [Related]  

  • 36. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.
    Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM
    Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of antileukemic agents employing advanced leukemia L1210 in mice. VII.
    Venditti JM; Sheldon DR; Goldin A
    Cancer Res; 1964 Jan; 24(1 Pt 1):145-210. PubMed ID: 5878215
    [No Abstract]   [Full Text] [Related]  

  • 38. Sequential biochemical alteration to antifolate resistance in L1210 leukaemia.
    Sirotnak FM; Kurita S; Sargent MG; Robinson DL; Hutchison DJ
    Nature; 1967 Dec; 216(5121):1236-7. PubMed ID: 5235641
    [No Abstract]   [Full Text] [Related]  

  • 39. New approaches to chemotherapy.
    Hutchison DJ
    Ann N Y Acad Sci; 1971 Nov; 186():496-500. PubMed ID: 5002440
    [No Abstract]   [Full Text] [Related]  

  • 40. Lack of intracellular conversion of dihydrohomofolate to tetrahydrohomofolate in leukemia cells with high levels of dihydrofolate reductase.
    Nahas A; Friedkin M
    Mol Pharmacol; 1972 May; 8(3):353-61. PubMed ID: 5040933
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.